RESULTS
A total of 2454 out of 3646 patients were assessed, where in 79.8% of patients “diagnosis to surgery time” was less than or equal to 90 days. Groups were distributed similarly with respect to PSA value on diagnosis, Gleason grade groups of biopsy pathology and D’amico risk-group classification. Pathological findings of the RP specimens were similar between two groups with respect to surgical margin status, lymph node positivity and extracapsular extension. However, there was slightly more seminal vesicle invasion in final surgical pathology in group 1 (12.9% vs. 9.3%, respectively p=0.042). Considering the low-risk patients, Gleason score upgrading was observed in 37.94% of group 1 compared to 30.56% of group 2 (p=0.046). 5-year biochemical recurrence free survival times were similar across all D’Amico risk categories between two groups. In high-risk patients the need for adjuvant treatment was higher in group 1 (40.8% vs. 25% respectively, p=0.023), whereas there was no statistically significant difference between groups with respect to metastasis- and PSA recurrence rate. The regression analysis demonstrated the seminal vesicle invasion as the only factor affecting time to PSA progression in high-risk patients (p<0.001 HR:2.51 CI: 1,58-4,45).